

LEVERAGING ANTIBODY-DRUG CONJUGATES IN CANCER CARE:

Evolving Approaches to Bridge Clinical Gaps in Breast, GI, and Lung Tumors

TUESDAY, SEPTEMBER 21, 2021

10:30 – 12:00 CEST • Channel 3

PROGRAM CHAIR



Cristina Saura
Head, Breast Cancer Unit
Medical Oncology Service
Vall d'Hebron University
Hospital
Barcelona, Spain

FACULTY



Yelena Y. Janjigian, MD
Associate Professor
Chief, Gastrointestinal
Oncology Service
Department of Medicine
Memorial Sloan Kettering
Cancer Center
New York, NY



Maurice Pérol, M.D.
Head of Thoracic
Oncology Program
Léon Bérard Cancer
Centre
Lyon, France

OVERVIEW

Antibody-drug conjugates (ADCs) consist of a monoclonal antibody linked to a cytotoxic agent that targets tumor cells while sparing healthy cells. There are 3 ADCs targeting HER2 and TROP2 that are approved for the treatment of patients with solid tumors, and several others are in various stages of development in clinical trials. Adverse events commonly associated with ADCs include interstitial lung disease that requires prompt intervention and mitigation so patients derive optimal benefit from their therapies without interruptions or discontinuations.

Leveraging Antibody-Drug Conjugates in Cancer Care: Evolving Approaches to Bridge Clinical Gaps in Breast, GI, and Lung Tumors is a virtual satellite symposium designed to help physicians assess the latest available data on ADCs in breast, gastrointestinal (GI), and lung cancers. Renowned experts will discuss the mechanism of action, efficacy, and safety of currently available ADCs. Applications of approved ADCs, biomarker testing, and emerging data for ADC treatment approaches across cancer care will be presented. Question-and-answer sessions will allow oncologists to ask about the utility of ADCs in the treatment of solid tumors, ultimately providing insight into how the experts approach treatment decisions for patients with breast, GI, and lung cancers.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Daiichi Sankyo

AGENDA

10:30	Welcome and Introductions	Cristina Saura
10:35	Unmet Educational and Clinical Needs in Biomarker Testing: Key Concepts for the Multidisciplinary Team	Cristina Saura
10:45	Novel HER2/3 and TROP2 Approaches in Breast Cancer: Integrating Recent Evidence	Cristina Saura
11:05	Question & Answers Session (Live)	
11:10	A New Wave of Developments on HER2 Targeted Strategies in Gastric Cancer and Beyond: Implications for Testing and Treatment	Yelena Janjigian
11:30	Question & Answer Session (Live)	
11:35	Exploring Unmet Needs in Advanced NSCLC: Rationale for Emerging Approaches Targeting HER2, HER3, TROP2, and Beyond!	Maurice Pérol
11:55	Question & Answer Session (Live)	
12:00	Closing Remarks & Adjourn	Cristina Saura

